Search

for
Search:

Sort by

Research

240-270 / 1000+ results

research Are finasteride-related penile curvature/Peyronie’s disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases

2 citations , May 2022 in “International Journal of Impotence Research”

Finasteride may be linked to Peyronie’s disease, but more research is needed.

research FDA Approved pediatric antihypertensive agents

1 citations , January 2014 in “Digital Commons@Becker (Washington University School of Medicine)”

FDA-approved medications are important for treating high blood pressure in children, but non-approved ones can be used if needed.

research Impact of Reporter Type on Signal Detection of Cancer Therapy-Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System

March 2026 in “Pharmaceuticals”

Reporter characteristics affect detection of hair loss from cancer therapy.

research Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases

October 2025 in “Frontiers in Medicine”

Ixekizumab has known and some unexpected side effects.

research 62202 Network meta-analysis (NMA) of FDA-approved JAK inhibitors for alopecia areata (AA) with at least 50% hair loss per SALT score

September 2025 in “Journal of the American Academy of Dermatology”

Some JAK inhibitors are effective for significant hair regrowth in alopecia areata.

Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports

research Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports

June 2025 in “Pharmaceuticals”

Finasteride use may increase suicidality risk, especially in young men.

Multidimensional Assessment of Adverse Events of Finasteride: A Real-World Pharmacovigilance Analysis Based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024

research Multidimensional assessment of adverse events of finasteride：a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024

March 2025 in “PLoS ONE”

Finasteride can cause long-term side effects like sexual dysfunction and depression.

research Cyclosporine-induced alopecia:a case report, FDA adverse event reporting system analysis and literature assessment

August 2024 in “Frontiers in Pharmacology”

Cyclosporine may cause hair loss, so patients need monitoring.

The FDA Approves Litfulo® (Ritlecitinib) for the Treatment of Severe Alopecia Areata in Adolescents and Adults

research La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos

September 2023 in “Medicina Estética Revista Científica de la Sociedad Española de Medicina Estética (SEME)”

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.

FDA-Approved (Bremelanotide, Flibanserin) and Off-Label Medications (Testosterone, Sildenafil) to Enhance Sexual Desire and Function in Women

research FDA-Approved (Bremelanotide, Flibanserin) and Off-Label Medications (Testosterone, Sildenafil) to Enhance Sexual Desire/Function in Women

April 2020 in “Online journal of complementary & alternative medicine”

Some medications can help increase sexual desire and function in women.

research Novel acne cream seeks FDA approval

October 2019

A new acne cream effectively reduced acne in trials and awaits FDA approval.

research FDA approves label addition for PDE-5 inhibitor

October 2013 in “Urology Times eNews”

The FDA approved using Cialis with Proscar for better treatment options.

research FDA vetoes labelling proposals for finasteride, dutasteride

December 2010 in “Reactions Weekly”

research Retrospective Pharmacotherapeutic Evaluation of Dutasteride not Approved by US FDA for Androgenetic Alopecia in Korea

September 2015 in “Korean Journal of Clinical Pharmacy”

Dutasteride is highly effective for hair loss treatment in Korea, with more side effects than finasteride.

research Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods

42 citations , April 2021 in “Pharmaceuticals”

Five FDA-approved drugs may help block COVID-19 virus entry.

research Non-FDA-Approved Uses of Apremilast in Dermatology: A Review of Current Available literature

1 citations , September 2022 in “Nepal journal of dermatology, venereology & leprology”

Apremilast shows promise for several skin conditions but needs more research.

research Unequal Protection Under the Law: Why FDA Should Use Negotiated Rulemaking to Reform the Regulation of Generic Drugs

1 citations , January 2013 in “Scholar Commons (University of South Carolina)”

The FDA should use negotiated rulemaking to improve generic drug safety regulations.

research Repurposing FDA approved drugs for psoriasis indications through integrated molecular docking, one-SVM algorithm, and molecular dynamics simulation approaches

July 2025 in “Scientific Reports”

Pioglitazone, Trimipramine, and Dimetindene may be repurposed to treat psoriasis.

research Host-directed FDA-approved drugs with antiviral activity against SARS-CoV-2 identified by hierarchical in silico/in vitro screening methods

November 2020 in “bioRxiv (Cold Spring Harbor Laboratory)”

Five FDA-approved drugs may help block COVID-19 virus entry.

research Not Its Crowning Glory: Obstacles for FDA in Regulating Ingested Dietary Supplements Purporting to Prevent Hair Loss

January 2005 in “Digital Access to Scholarship at Harvard (DASH) (Harvard University)”

The FDA struggles to regulate hair loss supplements due to a law allowing unproven claims.

The Possible Role of Prescribing Medications in Contributing to Male-Factor Infertility: Assessment of the FDA Pharmacovigilance Database

research The Possible Role of Prescribing Medications, Including Central Nervous System Drugs, in Contributing to Male-Factor Infertility (MFI): Assessment of the Food and Drug Administration (FDA) Pharmacovigilance Database

November 2023 in “Brain Sciences”

Some medications might contribute to male infertility, with finasteride showing a high number of reports.

Repurposing of Linagliptin and Similar FDA Approved Drugs as Antidiabetic Agents

research Repurposing of Linagliptin Similar FDA Approved Drugs as Antidiabetic Agents

May 2021 in “Letters in Applied NanoBioScience”

Pranlukast and mirabegron may work as new diabetes drugs.

research The US FDA has approved the marketing of generic finasteride 5mg tablets by Actavis.

May 2007 in “Inpharma Weekly”

research Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System

11 citations , July 2020 in “Scientific Reports”

Statins may be linked to reproductive organ conditions, and their risks should be monitored.

Cutaneous Adverse Reactions Associated With Enfortumab Vedotin: A Pharmacovigilance Study Based on the FDA Adverse Event Reporting System

research Cutaneous adverse reactions associated with enfortumab vedotin: a pharmacovigilance study based on the FDA adverse event reporting system

April 2026 in “Frontiers in Medicine”

Enfortumab vedotin can cause skin issues, especially in older males, needing early monitoring.

Safety Concerns of Paternal Drug Exposure on Fertility, Pregnancy, and Offspring: An Analysis Based on the FDA Adverse Event Reporting System

research Safety concerns of paternal drug exposure on fertility, pregnancy and offspring: An analysis based on the FDA adverse event reporting system

October 2024 in “Andrology”

Paternal drug exposure can harm fertility, pregnancy outcomes, and offspring health, with specific drugs linked to various reproductive issues.

research 112 Post-Finasteride Syndrome – Outcomes of FDA Database

April 2016 in “The Journal of Sexual Medicine”

research Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System

58 citations , March 2020 in “Scientific Reports”

EGFR-TKIs can cause significant skin, nail, and organ side effects.

research Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system

30 citations , January 2024 in “Frontiers in Pharmacology”

These migraine prevention drugs can cause side effects like constipation, hair loss, injection site reactions, fatigue, and sometimes unexpected issues like Raynaud's phenomenon and weight gain.

research Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024

8 citations , May 2025 in “Pharmaceuticals”

In 2024, the FDA approved 27 innovative small-molecule drugs, with many offering significant treatment improvements.

← Previous page Next page →